Biotts has achieved a significant scientific and commercial milestone with the publication of new peer-reviewed data in the prestigious journal Frontiers in Pharmacology.

Biotts publishes peer-reviewed research in Pharmaceutics (MDPI) validating MTC-Y™ technology for transdermal delivery of lidocaine and tetracaine.

Biotts has been granted US Patent No. 12,478,679 B2 for its MTC-Y transdermal carrier technology. The patent was issued by the USPTO on 25 November 2025.

Biotts represented Polish transdermal innovation at BioJapan 2025 in Yokohama, Japan – Asia’s premier bio-industry partnering event. Read about our experience.

At Biotts, we offer tailored, GMP-compliant research and development services specifically designed to meet the rigorous needs of pharmaceutical, biotechnology, cosmetics, and dietary supplements companies. Our multidisciplinary team, supported by advanced GMP-certified laboratories, ensures comprehensive project support from initial formulation through to analytical validation.